Skip Navigation

Search By:

XX-XXX

Refine by:

47 Clinical Trials Found

Enrolling

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

This phase II trial studies how well neratinib with or without fulvestrant works in treating patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer that carries HER2 gene mutations and has spread to other parts of the body (metastatic). Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can stimulate the...

  • Phase: II
  • Trial ID: NCT01670877

Not Enrolling

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers

This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Palbociclib may stop the growth of tumor cells by blocking some of the...

  • Phase: II
  • Trial ID: NCT02384239

Not Enrolling

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used...

  • Phase: II
  • Trial ID: NCT02614794

Enrolling

A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

  • Phase: II
  • Trial ID: NCT02779751

Not Enrolling

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced ER+ and AR+ breast cancer in postmenopausal women.

  • Phase: II
  • Trial ID: NCT02463032

Not Enrolling

An open-label, phase Ib/II clinical trial of CDK 4/6 inhibitor, ribociclib (LEE011), in combination with trastuzumab or TDM-1 for advanced/metastatic HER2-positive breast cancer.

This phase Ib / II trial studies the best dose of ribociclib with trastuzumab or trastuzumab emtansine and to see how well they work in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or other places in the body and is human epidermal growth factor receptor 2 (HER2)-positive. Ribociclib may stop the growth of tumor cells by blocking some...

  • Phase: I/II
  • Trial ID: NCT02657343

Enrolling

A Phase 1b/2a Study Of Palbociclib In Combination With Everolimus And Exemestane In Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer.

This phase Ib / IIa trial studies the side effects and best dose of palbociclib and everolimus and how well they work when given together with exemestane in treating patients with estrogen receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer that has spread to other places in the body. Palbociclib, everolimus, and exemestane may stop the growth of tumor...

  • Phase: I/II
  • Trial ID: NCT02871791

Enrolling

A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide) for breast cancer that has spread to other parts of the body.

  • Phase: I
  • Trial ID: NCT02057133

Enrolling

A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer.

This study will examine the safety and tolerability of SGN-LIV1A (ladiratuzumab vedotin) in patients with metastatic breast cancer. SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.

  • Phase: I
  • Trial ID: NCT01969643

Enrolling

A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian, fallopian tube, peritoneal cancer or recurrent triple-negative breast cancer

This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back. Olaparib and onalespib may stop the growth of tumor cells by blocking some of...

  • Phase: I
  • Trial ID: NCT02898207

Enrolling

Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma

This trial studies how well radiation therapy works in assessing patient outcomes after breast reconstruction surgery for invasive breast cancer. Giving radiation therapy in different ways may help doctors better understand how radiation therapy effects quality of life, cosmetic outcomes, and the side effects of radiation therapy.

  • Phase: III
  • Trial ID: NCT03422003

Enrolling

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

This phase II trial studies how well olaparib works in treating patients with breast cancer that has spread to other places in the body and has deoxyribonucleic acid (DNA) repair mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in patients with metastatic breast cancer.

  • Phase: II
  • Trial ID: NCT03344965

Enrolling

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis

This phase II trial studies how well atezolizumab and stereotactic radiosurgery work in treating participants with stage IV triple negative breast cancer that has spread to the brain. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiation is a...

  • Phase: II
  • Trial ID: NCT03483012

Not Enrolling

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or...

  • Phase: III
  • Trial ID: NCT01901094

Enrolling

AVIATOR: A randomized, phase II study comparing trastuzumab and vinorelbine in combination with avelumab or avelumab and utomilumab (41BB/CD137 agonist), in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab and pertuzumab

This phase II trial studies the how well trastuzumab, vinorelbine tartrate, and avelumab with or without utomilumab work in treating patients with HER2-positive breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as trastuzumab, avelumab, and utomilumab, may induce changes in the body's immune system and may interfere with the ability of tumor...

  • Phase: II
  • Trial ID: NCT03414658

Enrolling

"A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2-POSITIVE BREAST CANCER"

This first-in-human, Phase 1, open-label, multicenter, dose-escalation study will evaluate the safety, tolerability, and PK of DHES0815A as a single agent in participants with advanced and / or metastatic HER2-positive breast cancer for whom established treatment has proven ineffective or intolerable or is unavailable. The study may include a dose-expansion cohort (based on an ongoing assessment...

  • Phase: I
  • Trial ID: NCT03451162

Enrolling

A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

This randomized phase II trial studies how well carboplatin with or without pembrolizumab work in treating patients with breast cancer that has spread to other places in the body with chest wall disease that has come back and cannot be removed by surgery. Monoclonal antibodies, such as carboplatin and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

  • Phase: II
  • Trial ID: NCT03095352

Not Enrolling

A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer

This phase II trial studies how well nivolumab and cabozantinib work in treating patients with triple negative breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells...

  • Phase: II
  • Trial ID: NCT03316586

Enrolling

A Phase Ib/II Study of Olaparib with Sapacitabine in BRCA Mutant Breast Cancer

This phase Ib / II trial studies the side effects and best dose of sapacitabine when given together with olaparib and to see how well they work in treating patients with BRCA mutant breast cancer that has spread to other parts of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,...

  • Phase: I/II
  • Trial ID: NCT03641755

Enrolling

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC)

This phase Ib trial studies how well XBP1-unspliced (XBP1-US) / XBP1-spliced (XBP1-SP) / CD138 / CS1 multipeptide vaccine PVX-410 (PVX-410) and pembrolizumab work in treating patients with human leukocyte antigen (HLA)-A2 positive triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to...

  • Phase: I
  • Trial ID: NCT03362060

Enrolling

Smartphone Technology to Alleviate Malignant Pain (STAMP): development and piloting of a novel mHealth intervention to support cancer patients, nurses, and physicians in opioid management

This trial studies how well Smartphone Technology to Alleviate Malignant Pain works in helping opioid management in cancer patients, nurses, and physicians. Smartphone Technology to Alleviate Malignant Pain may help to support patient self-management through education, patient-reported outcome assessment and medication reminders; offer tailored decision-support to both patients and providers; and...

  • Phase: Not Applicable
  • Trial ID: NCT03717402

Enrolling

Phase 1/2, Multicenter, Open-Label, Multiple Dose, First-In-Human Study of U3-1402, in Subjects with HER3 Positive Metastatic Breast Cancer

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical...

  • Phase: I/II
  • Trial ID: NCT02980341

Enrolling

A Phase 2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination with Talazoparib in Patients with BRCA or ATM Mutant Tumors

Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.

  • Phase: II
  • Trial ID: NCT03565991

Enrolling

A Phase Ia/Ib, Multicenter, Open-label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and / or luteinizing hormone−releasing hormone (LHRH) agonist in patients with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

  • Phase: I
  • Trial ID: NCT03332797

Not Enrolling

A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

  • Phase: II
  • Trial ID: NCT03248492

Enrolling

A Randomized Phase 2 Trial Of Carboplatin With Or Without Nivolumab In First- Or Second-Line Metastatic Triple-Negative Breast Cancer

This phase II trial studies how well carboplatin with or without nivolumab works in treating patients with triple-negative breast cancer that has spread to nearby tissues and lymph nodes or has spread to other places in the body and cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells,...

  • Phase: II
  • Trial ID: NCT03414684

Not Enrolling

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC) Patients will be treated until progression,...

  • Phase: III
  • Trial ID: NCT02574455

Enrolling

A phase II study of atezolizumab in combination with pertuzumab plus high-dose trastuzumab for the treatment of central nervous system metastases in patients with Her2-positive breast cancer

This phase II trial studies how well atezolizumab works when given together with pertuzumab and high-dose trastuzumab in treating participants with HER2-positive breast cancer that have spread to the central nervous system from other parts of the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, pertuzumab and trastuzumab, may help the body’s immune system attack the cancer,...

  • Phase: II
  • Trial ID: NCT03417544

Enrolling

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant for Women with Advanced, Endocrine-resistant Breast Cancer

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or...

  • Phase: II
  • Trial ID: NCT02860000